Jiang Huahua, Deng Yong, Zhang Yixin, Jin Jieli, Kong Xueying, Zhu Qiuwen, Wang Kuiyun, Zhou Jiying
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, 1st You Yi Road, Yu Zhong District, Chongqing, 400016, China.
Department of Neurology, The first people's Hospital of Jintang County, Sichuan, China.
J Headache Pain. 2016 Dec;17(1):85. doi: 10.1186/s10194-016-0678-x. Epub 2016 Sep 19.
Chronic headache (CrH) occurs commonly in the population, and chronic migraine (CM) accounts for much of the CrH. Diagnostic criteria for CM remain controversial, and this could lead to undertreatment of CM. The purpose of this study was to analyze the clinical profiles of CM and to field test the International Classification of Headache Disorders-3β criteria (ICHD-3β) and Expert Opinion criteria (EO) for CM application.
We retrospectively reviewed the medical records of CrH patients in our headache clinic during the period. Eligible patients were selected from CrH population based on Silberstein and Lipton criteria (S-L) for CM, and meanwhile fulfilled with migraine days at least 8 days/month. Then we evaluated the characteristics of clinic profiles and outcomes between patients diagnosed CM using ICHD-3β and EO criteria. Field tested the CM criteria Of ICHD-3β and EO.
In a total of 710 CrH patients , 261 (36.8 %) were recruited with CM based on both S-L criteria and fulfilled at least 8 migraine days/month. Be understandable, all the 261 patients met the EO criteria, and only 185 (70.9 %) met ICHD-3β for CM. For the 76 patients who met EO but not ICHD-3β, 70 had atypical migraine attacks (probable migraine, PM), and another 6 had typical migraine attacks but less than a total history of 5 attacks. Although 173 (66.3 %) were concurrent with medication overuse, just one patient overused triptans and none used ergot agents. Clinical features were not significantly different between the ICHD-3β and EO criteria groups (P > 0.05), and neither were outcomes of prophylaxis (P = 0.966). Total migraine prophylaxis effectiveness was 73 %.
Migraine-specific analgesics are rarely used in China, permitting patients with PM to avail themselves of "migraine days" is a reasonable accommodation for this difficult condition. In our hands, use of the new EO criteria for diagnosis of CM increases the sensitivity and maintains the specificity of decision making, and therefore should be adopted in CM management practice.
慢性头痛(CrH)在人群中普遍存在,慢性偏头痛(CM)占CrH的很大一部分。CM的诊断标准仍存在争议,这可能导致CM治疗不足。本研究的目的是分析CM的临床特征,并对国际头痛疾病分类第3版β标准(ICHD - 3β)和专家意见标准(EO)在CM应用方面进行现场测试。
我们回顾性分析了该时期我院头痛门诊CrH患者的病历。符合条件的患者根据CM的西尔伯斯坦和利普顿标准(S - L)从CrH人群中选取,同时每月偏头痛天数至少8天。然后我们评估了使用ICHD - 3β和EO标准诊断为CM的患者之间的临床特征和结局。对ICHD - 3β和EO的CM标准进行现场测试。
在总共710例CrH患者中,261例(36.8%)根据S - L标准被纳入CM组,且每月偏头痛天数至少8天。可以理解的是,所有261例患者均符合EO标准,而只有185例(70.9%)符合CM的ICHD - 3β标准。对于符合EO但不符合ICHD - 3β标准的76例患者,70例有非典型偏头痛发作(可能偏头痛,PM),另外6例有典型偏头痛发作但发作总数少于5次。虽然173例(66.3%)同时存在药物过度使用情况,但仅1例过度使用曲坦类药物,无人使用麦角制剂。ICHD - 3β和EO标准组之间的临床特征无显著差异(P>0.05),预防性治疗的结局也无显著差异(P = 0.966)。偏头痛预防性治疗的总有效率为73%。
偏头痛特异性镇痛药在中国很少使用,允许PM患者利用“偏头痛天数”是针对这种困难情况的合理调整。在我们的研究中,使用新的EO标准诊断CM可提高敏感性并维持决策的特异性,因此应在CM管理实践中采用。